SynthesisSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Social determinants of health in studies using PROMs to assess toxicities associated with immune checkpoint inhibitor treatment: a systematic review.
Synthesis in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeSocial determinants of health (SDOH) are associated with disparities not only in risk factors, screening, diagnosis, and treatment outcomes for cancer but also in access to immunotherapy treatment, particularly with immune checkpoint inhibitors (ICIs). The purpose of this systematic review was to describe the extent of inclusion of indicators of SDOH in studies using PROMs to assess toxicities associated with ICI treatment.
methodsPubMed, EMBASE, MEDLINE, PsycINFO, CINAHL, Web of Knowledge, and the Cochrane Library were searched for papers using patient-reported outcomes measures (PROMs) to assess toxicities in ICI treatment until October 2024.
resultsA total of 43 studies were included after applying the inclusion criteria, with the majority being RCTs (n = 20). SDOH features were extracted using the PROGRESS-Plus framework. The most frequently reported PROGRESS-Plus factors were residence (100%; 43/43), age (100%; 43/43), and gender (97.7%; 42/43). Race/ethnicity was included in 16 studies (37.2%) and education in 11 (25.6%). Very few studies reported socioeconomic status (11.6%; 5/43), social capital (9.3%; 4/43), and occupation (9.3%; 4/43). None of the studies included information on religion, disability, and sexual orientation.
conclusionCollection and consideration of SDOH in studies using PROMs to assess toxicities in ICI treatment in cancer care are limited. Reported SDOH are not sufficient as they overlook important characteristics such as religion, disability, and sexual orientation. Improved accuracy and details are essential in understanding the needs of various populations. Availability of these data will facilitate understanding of health inequalities and prompt action to address avoidable disparities in health, improving outcomes for all.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.